Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 12 publications
Phase I/II Trial of Vemurafenib in Dogs with Naturally Occurring, BRAF-mutated Urothelial Carcinoma.
Phase I/II Trial of Vemurafenib in Dogs with Naturally Occurring, BRAF-mutated Urothelial Carcinoma.
Journal: Molecular cancer therapeutics
Published: October 16, 2020
A Phase Ib Study to Evaluate the MEK Inhibitor Cobimetinib in Combination with the ERK1/2 Inhibitor GDC-0994 in Patients with Advanced Solid Tumors.
Journal: The oncologist
Published: March 24, 2020
A First-in-Human Phase I Study to Evaluate the ERK1/2 Inhibitor GDC-0994 in Patients with Advanced Solid Tumors.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: August 05, 2019
Absence of Pharmacokinetic Interactions between the Bruton's Tyrosine Kinase Inhibitor Fenebrutinib and Methotrexate.
Journal: The Journal of pharmacology and experimental therapeutics
Published: February 11, 2019
Phase I study of the checkpoint kinase 1 inhibitor GDC-0575 in combination with gemcitabine in patients with refractory solid tumors.
Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: May 23, 2018
Safety, Pharmacokinetics, and Pharmacodynamics in Healthy Volunteers Treated With GDC-0853, a Selective Reversible Bruton's Tyrosine Kinase Inhibitor.
Journal: Clinical pharmacology and therapeutics
Published: January 17, 2018
Phase I Study of GDC-0425, a Checkpoint Kinase 1 Inhibitor, in Combination with Gemcitabine in Patients with Refractory Solid Tumors.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: July 14, 2016
Emerging roles for the pro-oncogenic anterior gradient-2 in cancer development.
Journal: Oncogene
Published: September 05, 2012
Showing 1-12 of 12
Last Updated: 09/26/2026